



The Spanish National DNA bank infrastructure: promoting disease-oriented genetic/genome research

ESF-UB Conference
Biobanks: Introduction and Next Steps

Sant Feliu de Guixols, 5th November 2008





GENOME SPAIN INITIATIVE

banco a d n [©]

The National DNA Bank of Spain is a technological platform created in March 2004 by a collaboration agreement between Fundación Genoma España, Universidad de Salamanca and Consejería de Sanidad de la Junta de Castilla y León, with the aim of promoting genomic research in Spain.

NATIONAL DNA BANK of SPAIN

GENERAL GOAL

To promote and support research on genetic/genomic diversity associated with HEALTH, disease pathogenesis and therapy, and human evolution, with special emphasis on the population living in Spain.

- To identify genes in complex diseases.
- To dissect the role of environmental, social, nutritional and lifestyle factors in complex diseases.
- To promote research in pharmacogenomics (interaction between genes, phenotype and drug response).


National DNA Bank of Spain Major roles

- To obtain, process and store biological samples and their associated data.
- To provide DNA samples to research groups.
- To ensure a rational, effective, ethical and legal use of the available resources.

The real value of a biobank lies on the existence of "cooperative research projects of excellence".



STRUCTURE (until October 2006)






National DNA Bank of Spain Network of Blood Banks and Regional Transfusion Centers





STRUCTURE (until October 2006)






COHORT OF SAMPLES OF REFERENCE OF THE SPANISH POPULATION

All samples stored at the National DNA Bank of Spain contain associated information & informed consent.

N. of samples: 1003

Status: AVAILABLE


DISTRIBUTION ACCORDING TO SIZE OF PLACE OF BIRTH




DISTRIBUTION ACCORDING TO EDUCATION STUDIES



AGE DISTRIBUTION




GENDER DISTRIBUTION



Region (CCAA)	N. of samples received
Andalucía	154
Aragón	26
Asturias	25
Baleares (Islas)	26
Canarias	22
Cantabria	25
Castilla la Mancha	32
Castilla y León	69
Cataluña	157
Ceuta	10
Comunidad Valenciana	97
Extremadura	25
Galicia	94
La Rioja	25
Madrid	149
Melilla	12
Murcia	30
Navarra	25
Subtotal number of stored samples	1003




STRUCTURE (since October 2006)



RESEARCH GROUPS




STRUCTURE






NATIONAL DNA BANK of SPAIN CENTRAL NODE STRUCTURE



banco a d n @

NETWORK STRUCTURE



banco a d n [©]

ONCOLOGICAL DISEASES:

SOLID TUMORS:

Colorectal, breast, head & neck, lung and prostate

HEMATOLOGIC MALIGNANCIES:

Chronic lymphocytic leukemia, chronic myeloproliferative disorders, acute leukemias, Non-Hodgkin lymphomas

CARDIOVASCULAR DISEASES:

Hypertension, myocardial infarction, ictus, heart failure, auricular fibrillation

NEUROPSYCHIATRIC DISEASES:

Schizophrenia, Alzheimer, Parkinson, multiple sclerosis, amyotrophic lateral sclerosis, idiopathic cervical dystonia

METABOLIC DISEASES:

Diabetes Mellitus (type I), Diabetes Mellitus (type II), obesity, morbid obesity, dyslipemias, controls

N. of estimated samples: 4,350

N. of samples stored: 3,011

N. of estimated samples: 2,500

N. of samples stored: 1,514

N. of estimated samples: 2,300


N. of samples stored: 871

N. of estimated samples: 2.500

N. of samples stored: 1,899



POPULATION OF CASTILLA Y LEÓN: STUDY OF CARDIOVASCULAR RISK



COORDINATING NODE: Banco Nacional

de ADN

Director: Prof. Alberto Orfao de Matos

Consejería de Sanidad, JCyL: (Valladolid)

Project coordinator: Dr. Tomás Vega Alonso

N. of samples: 3,488

Status: Available

All samples have written informed consent restricted to research projects related to cardiovascular risk.



FIBROMIALGY AND CHRONIC FATIGUE SYNDROME



<u>COORDINATING NODE</u>: National DNA Bank of Spain Director: Prof. Alberto Orfao de Matos

<u>Fundación de Fibromialgia y Síndrome de Fatiga</u> Crónica:

Project coordinator: Dr. Antonio Collado Supporting Institution: Fundación de Afectados y Afectadas de Fibromialgia y Síndrome de Fatiga Crónica

N. of estimated samples: 3000

Available in October 2008: 989

The National DNA Bank of Spain and the Foundation for Fibromialgy and Chronic Fatigue Syndrome collaborate to support scientific research on patients with fibromialgy and chronic fatigue syndrome.



SPANISH NETWORK ON MASTOCYTOSIS: DNA/CELL BANK



COORDINATING NODE: Banco Nacional de

ADN

Director: Dr. Alberto Orfao de Matos

Red Española de Mastocitosis (REMA):

Project Coordinator: Dr. Luis Escribano

N. of estimated samples: 3000 (patients and

family members).

Available in October 2008: 167

The National DNA Bank of Spain and the REMA (Spanish Network on Mast cell disorders) cooperate to promote scientific research on mastocytosis.



"Singular and Strategic Projects" of the Ministry of Education and Science

"Determination of genetic predictors and therapeutic targets in immune mediated inflammatory diseases (IMID) using a whole genome strategy"

<u>Principal Investigator</u>: **Dra. Sara Marsal** (Fundación Institut de Recerca del Hospital Universitari Vall d'Hebron)

Project duration: 2007-2010

DISEASES:	N. SAMPLES
Rheumatoid Arthritis	3.000
Psoriasis	3.000
Crohn disease	3.000
Controls	3.000

TOTAL: 12,000*

ASSOCIATED INSTITUTIONS:

- Fundación Institut de Recerca del Hospital Universitari Vall d'Hebron
- Schering-Plough S.A.
- Universidad de Salamanca (Banco Nacional de ADN)
- Fundació Centre de Regulació Genòmica
- Universitat Pompeu Fabra CCT
- Hospital General Universitario Gregorio Marañón
- Fundación Privada Clinic per la Recerca Biomedica
- Barcelona Supercomputing Center
- Centro Nacional de Investigaciones Oncológicas
- Hospital Universitario de la Princesa

*3,388 collected samples



BNADN: AVAILABLE SAMPLES (2008)

Control population:	N.of samples	Cell lines
- Spanish population	1.840	1.000
- Population of Castilla y León	3.488	
- Nonagenarians	30	
Prevalent diseases:		
- Neuropsychiatric diseases	871	157
- Metabolic diseases	1.899	
- Cardiovascular diseases	1.514	238
- Oncological diseases	3.011	
Other diseases:		
- Fibromialgy and Chronic Fatigue Syndrome	1.231	
- Mastocytosis	167	
- Immune-mediated inflammatory diseases and cont	trols 3.388	
Total:	17 438	1 395

BNADN: OVERALL PROGRESS IN PROVIDING SERVICES

- 2004 Creation of the BNADN
- 2005 Collection representative of the Spanish healthy population (n=1,003).
- 2006 Incorporation of 4 nodes on major/frequent diseases
 - Population based collection of Castilla y León (n=3,488)
 - Fibromyalgia & chronic fatigue syndrome (n=242)
- 2007 New bank on Mastocytosis (August)
 - New bank on IMID (August)
 - New collection on population-based controls (November)
 - New extended bank on FM & CFS (January 2008)
 - New collections on major diseases (October 2006) Phonosodio




BNADN: OVERALL PROGRESS IN PROVIDING SERVICES

- 2008 Bank on Mastocytosis (n=167)
 - Bank on **IMID** (n=3,388)
 - New population-based controls (n=837)
 - New extended bank on FM & CFS (n=1.231)
 - New collections on major diseases (n=7.295)
 - New banks with Working Groups of:
 Spanish Society of Internal Medicine (July)
 Spanish Society on Atherosclerosis


	2004	2005	Year 2006	2007	2008	
N. of samples	160	1,003	4,733	10,435	17,438	banco a d nº

Laboratory Integrated Management System





SAMPLE* FRACTIONING



^{*} Also tumour tissues, urine, mRNA, miRNA, depending on disease type



National DNA Bank of Spain ASSOCIATED DATA

Epidemiologic questionnaire:

-General Health (familiar antecedents)

- Nutritional and lifestyle habits (smoking, alcohol, physical activity...)
- Demographic data
 (family, place of living, culture...)
- **Genealogic data** (two generations)
- Phenotypic data
 (biochemical analysis, virology, anthropometrical measurements)

Disease questionnaire:

(Specific for each type of disease)

Data always included:

- Clinical data
- Diagnostic data
- Outcome data
- Associated diseases



EQUIPMENT RESOURCES

INTEGRATION SOFTWARE:

LIMS (VITRO S.A.) specifically developed by Vitro SA and the BNADN

AUTOMATION:

Automatic DNA extraction Robot, Autopure LS (GENTRA)

Spectrophotometers and fluorimeter, Nanodrop (Nanodrop Technologies) and GENios (TECAN)

Liquid handler robots, GENESiS 150 and freedom EVO (TECAN): aliquoting

2D code microtube aliquoting system (*Micronic®*)

Programmable cell fridge, *Criomed* (*Thermo*)

BIOSAFETY:

Biosafety Level III laboratory (50m²): Cell line production

Biosafety cabinets (Bio IIA): Sample processing and cell culture

STORAGE:

Stabilized freezer 4°C (Thermo): DNA (short term storage)

Mechanical freezers -80°C: plasma and DNA (long term storage)

Vapor phase liquid nitrogen (CBS Scientific): lymphocytes and cell lines



QUALITY MANAGEMENT SYSTEM


The National DNA Bank has developed, documented and implemented a quality management system (QMS) according to UNE-EN-ISO 9001:2000 model, as a basic strategy for increasing the user's and other interested parties satisfaction by guarantying the fulfillment of the requirements.

Certified: February 2006,






STRUCTURE (since October 2006)



Annual Report & Plan



STRUCTURE (since October 2006)






Access to DNA samples


Research groups: National, European and International (in collaboration projects with Spanish groups)

Research projects: "of scientific interest" and favorable evaluated by the External Committees.







EXTERNAL ACCESS TO DNA SAMPLES




OTHER SERVICES



VISITS AND TRAINING COURSES



BNADN: EVALUATION OF SERVICES BY USERS



Users overall rating (scale 0-5): 4,7

- Q1. The communication between the DNA Bank and the researcher is fluid
- Q2. The DNA Bank answers satisfactorily all the technical questions proposed
- Q3. The information given in the DNA Bank web is sufficient and clear
- Q4. To contact with the DNA Bank is easy
- Q5. The DNA Bank comply with the established periods for approving the project
- Q6. The researcher agrees with the commitments acquired when requesting the products
- Q7. Service rates are appropriate
- Q8. The DNA Bank has delivered all the requested products.
- Q9. The DNA Bank has complied with the established periods for delivering products.
- Q10. The products have arrived in the appropriate conditions.
- Q11. The DNA quality offered is adequate for the research project.
- Q12. The DNA quantity received is sufficient.




International Structure Estonian GenomEUTwin Project Biobank P₃G (Public Population Project in Genomics) "Harmonizacion of Biobanks and population-based cohorts" Cartagene/ UK Biobank Genome Canada **BancoADN** BBMRI (Biobanking and Biomedical Research Infrastructure)



National DNA Bank FUNDING ENTITIES 2004/08

ENTITIES	AMOUNT
■ FUNDACIÓN GENOMA ESPAÑA (GE)	1.583.441,05 €
☐ UNIVERSIDAD DE SALAMANCA (USAL)	701.888,78 €
■ JUNTA DE CASTILLA Y LEÓN (JCL)	316.033,75 €
■ MINISTERIO DE SANIDAD Y CONSUMO (MSC)	115.184,39 €
■ MINISTERIO DE EDUCACIÓN Y CIENCIA (MEC	498.760,00 €
☐ CAJA DUERO (CD)	7.468,75 €
■ ROCHE DIAGNOSTICS (RD)	15.000,00 €
■ INTERNAL RESOURCES (SERVICES)	25.399,96 €
TOTAL 3	.263.176,68€





LEGAL DEFINITION AND REGULATION OF BIOBANKS IN SPAIN

Ley de Investigación Biomédica (Law for Biomedical Research):

- 1. Genetic Analyses
- 2. Use of Biological samples
 - 3. Biobanks
- 4.- (Others: research using embryonic stem cells)

Artículo 3. - Biobanco: establecimiento público o privado, sin animo de lucro, que acoge una colección de muestras biológicas concebida con fines diagnósticos o de investigación biomédica y organizada como una unidad técnica con criterios de calidad, orden y destino



INFORMED CONSENT (INFORMATION)

Purpose

Expected benefits

Potential inconveniences

ID responsible for the research

Site of analysis & destination*

Right to know the Genetic results (data)

Right to revoke the consent & consequences

Guarantee of confidenciality

Implications on donor's health

Familial implications

Further contact



LEY DE INVESTIGACIÓN BIOMÉDICA collections of samples vs biobanks

Research Biobanks

National Banks

Collections for "personal" use

Collections for patient care purposes



SPANISH LAW ON BIOMEDICAL RESEARCH: obligations for the biobank

- Authorized by the regional governments (created by the Ministry of Health)
- Structure of the organization:
 - Scientific director & person responsible for "database"
 - External Committees

- Activities:

- To ensure fulfilling all legal requirements
- Registry of activities
- Guarantee of quality, safety & traceability of samples, data y procedures
- Attend to enquires & claims
- Good-practice manual/documentation INSPECTED

- Annual report



BIOBANK REGISTRY

for biomedical research

ISCiii

Regional Governments


Research Biobanks Other collections

Collections for health care purposes

Collections for "personal" use



SPANISH LAW ON BIOMEDICAL RESEARCH: Informed consent(s)



HAND OVER TO A THIRD PARTY



FUTURE DEVELOPMENT

New legal frame (strategic plan)

EXPAND SERVICES



- -New technologies
- -New collaborations
- -New services
- -New nodes

NEW ACTIVITIES



- Pre-analytical issues
- Cell purification
- Cryobiology

Biobanking Education:

- EQC program
- Master degree





www.bancoadn.org





THANKS TO ALL DONORS

www.bancoadn.org

Ana Bosch Ana María Regalado Andrés García Montero Flisabet Vilella Enrique de Álava Jaume Marrugat Javier García Palomo Juan Manuel María Almeida Parra María Isabel Morante Arroyo MaríaTeresa Marquez de Sousa Marta Aymerich Ramón Gomis Roberto Elosua Rosa Pinto Labajo Sheila Mateos Dominguez



National DNA Bank

WEAKNESSES:

- Lack of an appropriate legal framework for the development of the DNA bank:
 - Low flexibility on hiring personnel
 - Difficulties on applying for grants
 - Impact on "corporate image" (e.g.: a scattered network)
- Lack of a stable financial support at medium/long-term (Currently: yearly plan)
 - Negative impact on adequate planning
- Lack of a medium/long term (approved) strategic plan
 - Imbalanced ratio between collaborations/laboratory facilities
 - Limited coordination with other initiatives
- Difficulties on donor recruitment



National DNA Bank: Strengths

- Assumption of the acquired commitments
- Robustness of its structure and organization
- Strength of the networks and collaborations
- Specialized education of the BNADN professionals
- Ethical and legal frame/structure
- Quality of the samples and associated information
- Cost-effective project
- Strategic plan



MAIN FUTURE GOALS

SHORT TERM (2008)

- Integration of the four new nodes
- Implementation of an external quality control program for biobanks
- Development and implementation of a communication plan for users and donors

MEDIUM TERM (2008-2010)

NEW TECHNICAL IMPLEMENTATIONS:

- Whole genome amplification
- New immortalization approaches for different tissues
- Automated cell line generation facilities

OPTIMIZATION OF COLLECTIONS OF SAMPLES

- Population-based studies:
 - Representative of the population living on Spain
 - Minimum sample number (estimated): 60 per million inhabitants
- Disease-based studies:
 - Inflammatory diseases (n=9.000)
 - Thromboembolic diseases (to be determined)

LONG TERM (2007-2016)

INCREASE NUMBER AND TYPE OF SAMPLES: Rare diseases, TRANSCRIPTOMICS (mRNA):

- cell separation and purification
- mRNA extraction

IMPLEMENTATION OF PHENOTYPIC STUDIES



NEW EQUIPMENT AND STAFF REQUIREMENTS

MEDIUM TERM (3 years)

EQUIPMENT:

- New (larger) building facilities:
 - Storage laboratory and freezers
- Automation for whole genome amplification
 - Liquid handler PCR preparation robot
- Automation of cell line generation
 - Cell line production cabin
- Automation for whole genome amplification
 - Liquid handler PCR preparation robot

Additional STAFF:

- 2 laboratory technicians and 1 bachelor in science

LONG TERM (10 years)

EQUIPMENT:

- Equipment for phenotypic studies (e.g.: biochemical analyzer)
- Equipment for cell purification/isolation (e.g. AutoMACS)
- Automated mRNA extraction robot

Additional STAFF:

- 2 laboratory technicians and 2 bachelors in science 📆

